Table 1 Clinicopathological significance of ARL6IP5 expression in ovarian high-grade serous carcinoma patients.
Characteristic | ARL6IP5 expression | p-value | ||||
|---|---|---|---|---|---|---|
Negative (%) | Weak (%) | Moderate (%) | Strong (%) | |||
Age (years) | ≤60 | 7 (77.8) | 10 (43.5) | 22 (62.9) | 8 (66.7) | 0.249 |
>60 | 2 (22.2) | 13 (56.5) | 13 (37.1) | 4 (33.3) | ||
Serum CA 125 level (U/mL) | ≤3600 | 5 (55.6) | 17 (73.9) | 25 (71.4) | 6 (50.0) | 0.405 |
>3600 | 4 (44.4) | 6 (26.1) | 20 (28.6) | 6 (50.0) | ||
Germline BRCA mutation status | Wild type | 5 (55.6) | 8 (34.8) | 16 (45.7) | 8 (66.7) | 0.570 |
VUS | 1 (11.1) | 3 (13.0) | 4 (11.4) | 2 (16.7) | ||
Mutant | 0 (0.0) | 2 (8.7) | 1 (2.9) | 1 (8.3) | ||
NA | 3 (33.3) | 10 (43.5) | 14 (40.0) | 1 (8.3) | ||
FIGO stage | II | 3 (33.3) | 11 (47.8) | 12 (34.3) | 4 (33.3) | 0.719 |
III-IV | 6 (66.7) | 12 (52.2) | 23 (65.7) | 8 (66.7) | ||
Residual tumor after IDS (cm) | ≤0.5 | 6 (75.0) | 19 (90.5) | 26 (83.9) | 10 (83.3) | 0.763 |
>0.5 | 2 (25.0) | 9 (14.1) | 5 (16.1) | 2 (16.7) | ||
CRS | 1 | 2 (22.2) | 2 (8.7) | 4 (11.4) | 0 (0.0) | 0.225 |
2–3 | 7 (77.8) | 21 (91.3) | 31 (88.6) | 12 (100.0) | ||
Chemotherapeutic response | Respondant | 2 (22.2) | 18 (78.3) | 25 (71.4) | 11 (91.7) | 0.003a |
Resistant | 7 (77.8) | 3 (13.0) | 8 (22.9) | 0 (0.0) | ||
Refractory | 0 (0.0) | 2 (8.7) | 2 (5.7) | 1 (8.3) | ||
